美国市场对总体业绩贡献最大,不仅表现在绝对数字上,业绩增长也是由美国市场驱动(+7.8%),而国际市场则保持不动[1]。
2024第二季度新产品管线取得重大进展,包括Tremfya炎症性肠病(IBD)和皮下申请、Rybrevant皮下申请和VARIPULSE admIRE数据发布。
2024年上半年强生营收实现正增长,同时也在不断地扩充业务,快速以131亿美元完成对Shockwave的收购,但在考虑最近一系列收购产生的成本,强生下调了全年利润预测。该公司目前预计2024年调整后的每股营业利润为10.05美元,低于4月份发布的每股10.68美元的预期。
编者按:
强生不仅在全球药企营收排名中屡创佳绩,更以其稳健的市值表现,长期占据着行业巅峰。进入2024年,强生展现了出色的业绩,创新药物和医疗科技业务齐头并进,持续领航,不仅在肿瘤治疗和免疫疗法领域占据领先地位,更通过前瞻性收购策略,不断拓展其市场版图,为持续稳健的发展奠定了坚实基础。
参考文献(可上下滑动):
1. Johnson & Johnson reports Q2 2024 results
2. Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease
3. RYBREVANT®▼ (amivantamab) in combination with chemotherapy is the first 4. therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
5. C. Zhou et.al, Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions, N Engl J Med 2023;389:2039-51.
6. Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
6. Biosense Webster Presents Late-Breaking Data from admIRE Clinical Trial at the Heart Rhythm Society Annual Meeting
8. LBA0010 EFFICACY AND SAFETY OF NIPOCALIMAB, AN ANTI-FcRn MONOCLONAL ANTIBODY, IN PRIMARY SJOGREN’S DISEASE: RESULTS FROM A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY (DAHLIAS)
9. Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class
10. Johnson & Johnson to Acquire Shockwave Medical
11. Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
撰稿人 | 五月 药渡
责任编辑 | 邵丽竹
审核人 | 何发
2024-07-16
2024-06-20
2024-06-24
2024-06-27
2024-07-13
2024-06-27
2024-07-22
本文的目的是为了探讨不同清洗方法对分装器具的清洗效果。通过选取合适的污染物,以人工模拟污染的方式来污染各种直接接触产品的分装器具,然后对手工清洗、机械清洗的清洗流程以及清洗后取样检测总有机碳 (TOC)、电导率、细菌内毒素和微生物限度这 4 项指标进行比较分析。得出的结论为机械清洗的方法更具优越性,不仅提高了分装器具灭菌的质量,也降低了分装器具发生污染及交叉污染的风险。
作者:程露露 李欣
评论
加载更多